|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAP2K5 |
Gene summary for MAP2K5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAP2K5 | Gene ID | 5607 |
| Gene name | mitogen-activated protein kinase kinase 5 | |
| Gene Alias | HsT17454 | |
| Cytomap | 15q23 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q13163 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5607 | MAP2K5 | CCI_2 | Human | Cervix | CC | 2.03e-03 | 5.63e-01 | 0.5249 |
| 5607 | MAP2K5 | CCI_3 | Human | Cervix | CC | 6.87e-08 | 6.08e-01 | 0.516 |
| 5607 | MAP2K5 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.26e-08 | -4.68e-01 | 0.0155 |
| 5607 | MAP2K5 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.19e-03 | -4.38e-01 | 0.096 |
| 5607 | MAP2K5 | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.28e-02 | -4.57e-01 | 0.0338 |
| 5607 | MAP2K5 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.98e-08 | -3.39e-01 | 0.0674 |
| 5607 | MAP2K5 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.76e-24 | -6.12e-01 | 0.3859 |
| 5607 | MAP2K5 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.47e-21 | -5.54e-01 | 0.3005 |
| 5607 | MAP2K5 | F007 | Human | Colorectum | FAP | 5.49e-07 | -4.47e-01 | 0.1176 |
| 5607 | MAP2K5 | A001-C-207 | Human | Colorectum | FAP | 2.03e-03 | -3.30e-01 | 0.1278 |
| 5607 | MAP2K5 | A015-C-203 | Human | Colorectum | FAP | 4.54e-49 | -7.04e-01 | -0.1294 |
| 5607 | MAP2K5 | A015-C-204 | Human | Colorectum | FAP | 5.01e-13 | -5.76e-01 | -0.0228 |
| 5607 | MAP2K5 | A014-C-040 | Human | Colorectum | FAP | 5.26e-05 | -4.02e-01 | -0.1184 |
| 5607 | MAP2K5 | A002-C-201 | Human | Colorectum | FAP | 3.40e-17 | -3.81e-01 | 0.0324 |
| 5607 | MAP2K5 | A002-C-203 | Human | Colorectum | FAP | 8.66e-05 | -2.74e-02 | 0.2786 |
| 5607 | MAP2K5 | A001-C-119 | Human | Colorectum | FAP | 1.28e-14 | -7.25e-01 | -0.1557 |
| 5607 | MAP2K5 | A001-C-108 | Human | Colorectum | FAP | 2.64e-32 | -5.26e-01 | -0.0272 |
| 5607 | MAP2K5 | A002-C-205 | Human | Colorectum | FAP | 5.40e-30 | -7.12e-01 | -0.1236 |
| 5607 | MAP2K5 | A001-C-104 | Human | Colorectum | FAP | 1.20e-13 | -4.02e-01 | 0.0184 |
| 5607 | MAP2K5 | A015-C-005 | Human | Colorectum | FAP | 5.65e-05 | -3.84e-01 | -0.0336 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:200123310 | Cervix | CC | regulation of apoptotic signaling pathway | 96/2311 | 356/18723 | 4.08e-14 | 3.05e-11 | 96 |
| GO:005254710 | Cervix | CC | regulation of peptidase activity | 112/2311 | 461/18723 | 6.70e-13 | 3.08e-10 | 112 |
| GO:005254810 | Cervix | CC | regulation of endopeptidase activity | 103/2311 | 432/18723 | 1.89e-11 | 5.14e-09 | 103 |
| GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
| GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
| GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
| GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
| GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
| GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
| GO:001063210 | Cervix | CC | regulation of epithelial cell migration | 72/2311 | 292/18723 | 4.52e-09 | 4.43e-07 | 72 |
| GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
| GO:200011610 | Cervix | CC | regulation of cysteine-type endopeptidase activity | 61/2311 | 235/18723 | 8.69e-09 | 7.22e-07 | 61 |
| GO:00071626 | Cervix | CC | negative regulation of cell adhesion | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
| GO:004328110 | Cervix | CC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 55/2311 | 209/18723 | 2.77e-08 | 1.95e-06 | 55 |
| GO:004586110 | Cervix | CC | negative regulation of proteolysis | 80/2311 | 351/18723 | 2.88e-08 | 1.98e-06 | 80 |
| GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
| GO:00506787 | Cervix | CC | regulation of epithelial cell proliferation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
| GO:200123410 | Cervix | CC | negative regulation of apoptotic signaling pathway | 56/2311 | 224/18723 | 1.39e-07 | 6.70e-06 | 56 |
| GO:00513469 | Cervix | CC | negative regulation of hydrolase activity | 81/2311 | 379/18723 | 4.27e-07 | 1.67e-05 | 81 |
| GO:00104669 | Cervix | CC | negative regulation of peptidase activity | 60/2311 | 262/18723 | 1.27e-06 | 4.34e-05 | 60 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
| hsa0472214 | Cervix | CC | Neurotrophin signaling pathway | 32/1267 | 119/8465 | 5.01e-04 | 2.42e-03 | 1.43e-03 | 32 |
| hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
| hsa04540 | Cervix | CC | Gap junction | 22/1267 | 88/8465 | 9.07e-03 | 2.85e-02 | 1.69e-02 | 22 |
| hsa049218 | Cervix | CC | Oxytocin signaling pathway | 34/1267 | 154/8465 | 1.12e-02 | 3.42e-02 | 2.02e-02 | 34 |
| hsa05418110 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
| hsa0472215 | Cervix | CC | Neurotrophin signaling pathway | 32/1267 | 119/8465 | 5.01e-04 | 2.42e-03 | 1.43e-03 | 32 |
| hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
| hsa045401 | Cervix | CC | Gap junction | 22/1267 | 88/8465 | 9.07e-03 | 2.85e-02 | 1.69e-02 | 22 |
| hsa0492111 | Cervix | CC | Oxytocin signaling pathway | 34/1267 | 154/8465 | 1.12e-02 | 3.42e-02 | 2.02e-02 | 34 |
| hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
| hsa05418 | Colorectum | AD | Fluid shear stress and atherosclerosis | 54/2092 | 139/8465 | 1.41e-04 | 1.16e-03 | 7.37e-04 | 54 |
| hsa047221 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
| hsa054181 | Colorectum | AD | Fluid shear stress and atherosclerosis | 54/2092 | 139/8465 | 1.41e-04 | 1.16e-03 | 7.37e-04 | 54 |
| hsa054184 | Colorectum | MSS | Fluid shear stress and atherosclerosis | 51/1875 | 139/8465 | 6.06e-05 | 5.80e-04 | 3.55e-04 | 51 |
| hsa047224 | Colorectum | MSS | Neurotrophin signaling pathway | 45/1875 | 119/8465 | 7.04e-05 | 6.55e-04 | 4.02e-04 | 45 |
| hsa054185 | Colorectum | MSS | Fluid shear stress and atherosclerosis | 51/1875 | 139/8465 | 6.06e-05 | 5.80e-04 | 3.55e-04 | 51 |
| hsa047225 | Colorectum | MSS | Neurotrophin signaling pathway | 45/1875 | 119/8465 | 7.04e-05 | 6.55e-04 | 4.02e-04 | 45 |
| hsa054188 | Colorectum | FAP | Fluid shear stress and atherosclerosis | 45/1404 | 139/8465 | 3.05e-06 | 4.63e-05 | 2.81e-05 | 45 |
| hsa047226 | Colorectum | FAP | Neurotrophin signaling pathway | 38/1404 | 119/8465 | 2.49e-05 | 2.78e-04 | 1.69e-04 | 38 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAP2K5 | SNV | Missense_Mutation | rs766339386 | c.650N>G | p.Tyr217Cys | p.Y217C | Q13163 | protein_coding | deleterious(0.01) | probably_damaging(0.921) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
| MAP2K5 | SNV | Missense_Mutation | novel | c.532N>T | p.Gly178Cys | p.G178C | Q13163 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A97C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| MAP2K5 | deletion | In_Frame_Del | c.78_83delNNNNNN | p.Ser26_Ala28delinsArg | p.S26_A28delinsR | Q13163 | protein_coding | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |||
| MAP2K5 | SNV | Missense_Mutation | novel | c.218G>C | p.Arg73Thr | p.R73T | Q13163 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| MAP2K5 | SNV | Missense_Mutation | rs532904399 | c.343N>T | p.Arg115Trp | p.R115W | Q13163 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| MAP2K5 | SNV | Missense_Mutation | rs771473899 | c.320N>T | p.Arg107Ile | p.R107I | Q13163 | protein_coding | deleterious(0) | possibly_damaging(0.809) | TCGA-A6-6782-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| MAP2K5 | SNV | Missense_Mutation | c.82G>A | p.Ala28Thr | p.A28T | Q13163 | protein_coding | tolerated(0.24) | benign(0.18) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| MAP2K5 | SNV | Missense_Mutation | novel | c.206N>A | p.Arg69Gln | p.R69Q | Q13163 | protein_coding | deleterious(0.01) | probably_damaging(0.939) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MAP2K5 | SNV | Missense_Mutation | c.971N>T | p.Ala324Val | p.A324V | Q13163 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| MAP2K5 | SNV | Missense_Mutation | novel | c.40N>C | p.Asn14His | p.N14H | Q13163 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | AZD6244 | SELUMETINIB | |
| 5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | SELUMETINIB | SELUMETINIB | |
| 5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | WX-554 | WX-554 | ||
| 5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | TRAMETINIB | TRAMETINIB | |
| 5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | 328083482 | ||
| 5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | MEK162 | BINIMETINIB | |
| 5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | DABRAFENIB MESYLATE | ||
| 5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | 249565744 | ||
| 5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | GDC-0973 | COBIMETINIB | |
| 5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | BAY869766 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |